Q-PROTECT is a placebo controlled randomized trial (RCT) to ascertain the efficacy of hydroxychloroquine (HC) alone or, in combination with azithromycin (AZ), in reducing viral load in patients with COVID 19.
Reducing viral load is potentially key to reducing viral transmission between humans.
Observational data suggests HC and AZ may reduce the viral load. In this study we will
randomise ambulatory patients with Covid 19 (confirmed by PCR in combination with clinical
symptoms) to receive HC/AZ or HC/placebo or placebo for 7 days. On days 2-14, participants
will be reviewed by a member of the research team and samples will be obtained for viral
load, an ECG recorded and physical examination performed. On days 15-20, participants will be
reviewed by telephone using a semi structured questionnaire. On day 21 participants will be
examined in person and an oronasopharyngeal swabs obtained for PCR analysis. Participants
will be followed for 6 months via their medical records.
Drug: Hydroxychloroquine
Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days
Other Name: Plaquenil,
Drug: Azithromycin
Azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
Other Name: Zithromax, Azithrocin
Other: Placebo Tablet
Oral, one tablet three times a day for 7 days
Other: Placebo capsules
Oral 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
Inclusion Criteria:
- Patient is in HMC facility for low-acuity, Covid-positive patients being quarantined.
- Positive Covid test on qualitative assay used during routine care (i.e. not as part of
Q-PROTECT)
- Age at least 18
Exclusion Criteria:
- Treating physician judges patient not appropriate for study participation for any
reason
- Age <18
- Breastfeeding or pregnancy (patient-reported pregnancy status is sufficient)
- Hypersensitivity to chloroquine or HC or AZ
- History of or known QT prolongation
- EKG required before study entry and on each visit during the subject's first
seven days on pro-tocol, during the time period HC is being taken
- Baseline QTc >480 if QRS width normal; QTc >510 if QRS >120
- Known G6PD deficiency, porphyria, or retinopathy (eye exam prior to study entry)
- Known hepatic or renal disease (or abnormality on liver or renal function testing at
study day 1)
- Low magnesium or low potassium (by testing on day 1)
- Current (pre-study) therapy with antimalarial or dapsone
- Current (pre-study) therapy with antiviral agents (e.g. oseltamivir)
- Tisdale36 score exceeding 6 as tallied below (based on ACC recommendations)*
- 1 point each: age>67, female sex, or being on loop diuretic
- 2 points each: serum potassium <3.6, QTc>449, acute myocardial infarction
- 3 points each: sepsis, heart failure, QT-prolonging drugs
Hamad Medical Corporation
Doha, Qatar
Tim R Harris, Principal Investigator
Hamad Medical Corporation